Paion AG
SWB:PA8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Paion AG
SWB:PA8
|
DE |
Paion AG
PAION AG operates as a pharmaceutical company. The company is headquartered in Aachen, Nordrhein-Westfalen and currently employs 56 full-time employees. The company went IPO on 2012-03-29. The firm's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The firm operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.
PAION AG operates as a pharmaceutical company. The company is headquartered in Aachen, Nordrhein-Westfalen and currently employs 56 full-time employees. The company went IPO on 2012-03-29. The firm's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The firm operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
